New Assays: Microbicides for Prevention WEPDC2
Please enter your email :
Type:
Poster Discussion Back
Venue: Mini Room 3
Time: 13:00 - 14:00, 22.07.2009
Code: WEPDC2
Chairs: Jeanna Piper, United States
Lesley Erica Scott, South Africa
Session recording provided by International AIDS Society



Presentations in this session:

13:00
WEPDC201
Abstract
Powerpoint		Anti-HIV activity of the candidate microbicide maraviroc, a CCR5 receptor antagonist
Presented by Katherine Young, South Africa
P.S. Fletcher1, C. Herrera1, N. Armanasco1, A. Nel2, J. Nuttall3, J. Romano3, R.J. Shattock1
1St George's University of London, Centre for Infection, CMM, London, United Kingdom, 2International Partnership for Microbicides, Paarl, South Africa, 3International Partnership for Microbicides, Silver Spring, United States

13:10
WEPDC202
Abstract		A promising anti-STI/HIV molecule (SSP12) isolated from Indian mud crab Scylla serrata
Presented by K.V.R. Reddy, India
K.V.R. Reddy1, R. Yedery1, S. Gupta2, C. Aranha1
1National Institute for Research in Reproductive Health, Division of Molecular Immunology, Mumbai, India, 2National Institute of Immunology, Gamete Antigen Laboratory, New Delhi, India

13:20
WEPDC203
Abstract		Testing of new SHIV and HIV-1 chimeras containing the consensus HIV-1 subtype B and C clones from acute infections
Presented by Eric Arts, United States
Y. Gao1, K. Krebs1, R. Shattock2, N. Letvin3, B. Keele4, B. Hahn4, E.J. Arts1
1Case Western Reserve University, Cleveland, United States, 2St. George's Hospital, University of London, London, United Kingdom, 3Beth Israel Deaconess Medical Center, Harvard University, Boston, United States, 4University of Alabama at Birmingham, Birmingham, United States

13:30
WEPDC204
Abstract
Powerpoint		Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment
Presented by Andreas Meyerhans, Germany
S. Koch, A. Meyerhans, the GHRC and the CA-VIMC Consortium within the CAVD
Saarland University, Virology, Homburg, Germany

13:40
WEPDC205
Abstract
Powerpoint		Performance evaluation of the Determine® HIV 1/2 Ag/Ab Combo, a novel HIV 4th-generation rapid test
Presented by Falk Fish, Israel
T. Keren1, T. Guidasci2, B. Rivetz1, F. Fish1
1Inverness Medical, Yavne, Israel, 2Inverness Medical, Sevres, France

13:50
WEPDC206
Abstract
Powerpoint		Entry inhibition of HIV-1 subtype C from blood and vaginal mucosa by the lectins griffithsin, cyanovirin-N and scytovirin: potential HIV microbicides
Presented by Kabamba Bankoledi Alexandre, South Africa
K.B. Alexandre1, B. Lambson1, E. Gray1, R. Chikwamba2, K. Mlisana3, S.A. Karim3, J. McMahon4, B. O'keefe4, L. Morris1
1National Institute for Communicable Diseases, AIDS Research Unit, Johannesburg, South Africa, 2Centre for Scientific and Industrial Research, Pretoria, South Africa, 3CAPRISA, University of Kwa Zulu-Natal, Durban, South Africa, 4Center for Cancer Research, Frederick, United States

Powerpoints presentations
Anti-HIV activity of the candidate microbicide maraviroc, a CCR5 receptor antagonist - Young



Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment - Meyerhans

Performance evaluation of the Determine® HIV 1/2 Ag/Ab Combo, a novel HIV 4th-generation rapid test - Fish

Entry inhibition of HIV-1 subtype C from blood and vaginal mucosa by the lectins griffithsin, cyanovirin-N and scytovirin: potential HIV microbicides - Alexandre



Rapporteur report

Track C report by Vivian Black


The first presentation from Dr Young (IPM) showed a preclinical evaluation of maraviroc, a CCR5 Receptor Antagonist, to determine its suitability as a microbicide. The study results demonstrated that maraviroc is able to inhibit HIV-1 infection of ex-vivo genital and colorectal tissue and no change in activity was observed in the presence of biological fluids. The potency of maraviroc was shown to be increased through sustained delivery. Maraviroc, however, only had activity against CCR5 receptors with no effect on transfer of virus from migratory cells and levels of efficacy were low in some concentrations. These factors highlight that although maraviroc is a good candidate for development as a microbicide, it will need to be developed as a microbicide in combination with other ARVs.

 

Dr Reddy presented data on a Scylla serrata protein-12 (SSP12) molecule isolated from the Indian Mud Crab. Its activity against HIV was assessed using TZM-bl cell line.

The native and recombinant SSP12 molecule showed activity against several STI causing pathogens and HIV without causing damage to lactobacilli cells and may be a natural alternative to chemically based microbicides. Ongoing safety and toxicity studies are planned.

 

Eric Art presented data from Macaque studies looking at expanding SHIV challenge stock. There is currently only have one widely used SHIVenv virus which is non-pathogenic and largely homogeneous and which does not represent human exposure to diverse HIV viruses. Better models are required to test potential microbicide candidates.

 

Andreas Meyerhans looked at neutralizing antibody assays using centrally produced standardized HIV-1 Env-pseudovirus across 6 laboratories to assess whether the performance of these assays were concordant in the different sites. The study showed concordance in the proficiency tests across the labs. This centralized facility has the ability to produce and distribute pseudoviruses to different sites for use in vaccine or other research.

 

Dr Fish presented a study from nine clinical sites in Africa, Asia, Europe and Latin America to evaluate the performance of the Determine® HIV-1/2 Ag/Ab Combo test. The study included 1296 HIV positive and 2343 negative whole blood, plasma and serum specimens from various sources. The Determine® HIV-1/2 Ag/Ab Combo identified 108/117 (92.3%) of primary HIV infection specimens when compared to available 4th generation EIA and in seroconversion panels identified the infection on average 5 days (2-80 days) earlier than 3rd generation antibody tests which enables rapid identification of acute infection cases.

Lastly, Kabamba Alexandre, presented a study on three lectins (Griffithsin, Cyanovirin-N and Scytovirin) isolated from algae and cyanobacteria to assess their ability to inhibit HIV-1 subtype C entry by binding to glycans on gp120. His data showed that the lectins are potent inhibitors of HIV-1 subtype C virus from both plasma and CVL. Sensitivity may also be influenced by glycosylation sites. These compounds may be suitable microbicide candidates against the sexual transmission of HIV-1 subtype C. Further studies to look at, for example, escape mutants are ongoing.

 


   

   

    The organizers reserve the right to amend the programme.
Contact Us | Site map © 2009 International AIDS Society